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review of Medline and EMBASE databases was conducted for the period 2000 - 2013. 
The search sought to identify papers on the topic of assessment and reimburse-
ment policy for rare diseases. Health policy studies, commentaries, and review arti-
cles were included. Clinical or economic studies of specific drugs or diseases were 
excluded. Information was extracted on assessment and reimbursement challenges 
and author recommendations for addressing these issues. Results: The literature 
review identified 726 papers; 49 met the inclusion criteria. The most frequently 
identified issues included multiplicity of orphan indications (34/49), high per-patient 
cost (32/49), and the difficulty in undertaking robust clinical and economic evalu-
ations given limited evidence (32/49). Several authors commented on limitations 
of current health technology appraisal processes. The issue of equity and societal 
preference for funding rare diseases was highlighted in almost half of the papers 
(22/49). Lack of availability of alternative treatments was also considered an impor-
tant factor. Suggestions for improvements to the assessment and reimbursement 
process included: greater use of registries (22/49), adjustment to preference weights 
used in cost effectiveness analysis (19/49) and conditional reimbursement and risk-
sharing-schemes (12/49). Some authors advocated alternative pathways for assess-
ing rare disease treatments including a specific approach utilising multi-criteria 
decision analysis. ConClusions: The debate on payer policy in rare diseases has 
grown in the last 5 years as concerns have increased about patient access to new 
medicines. While there is some consistency in the literature, there is as yet little 
consensus on how policy should be changed to address these issues.
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objeCtives: Obesity prevalence is increasing worldwide, a worrying trend as it 
relates to many diseases and imposes significant direct and indirect health care 
costs. The purpose of the present study was to assess the impact of taxation 
policies upon the consumption of Sugar Sweetened Beverages (SSBs) and High 
in Fat Sugar and Salt (HFSS) foods and ultimately caloric intake and weight out-
comes. Methods: The review identified relevant papers from web-based searches 
in comprehensive databases such as: Pubmed, Web-of-Science, Cochrane Library, 
Ag Econ, Econlit and National Agricultural library. Searching was conducted 
with all potential combinations of various relevant for the purposes of the study 
financial, nutritional, and outcome terms. Thereafter, abstracts were reviewed and 
studies were selected based on predefined criteria. The search included studies 
published from 1990 up to February of 2013 in English language. The character-
istics and the results of the selected studies were extracted in a special form 
and consequently were reviewed and synthesized, based on the methodological 
design. Results: A total of fifty five studies were finally included in the review. 
Several different types of studies showed a reduction in purchases and consump-
tion of SSBs or HFSS foods when prices increase due or not due to taxation, but 
the subsequent effect upon total caloric intake was much smaller. A few studies 
which report weight outcomes, indicate that they are either insignificant or very 
small in magnitude to cause any public health improvements. ConClusions: 
The effectiveness of taxation policies to curb obesity levels is doubtful and the 
desired objectives not easily attainable, mainly because of the complex nature 
of consumer behavior and the impact of substitution effects, for which there is 
limited evidence to date. There is need to investigate in more depth the potential 
underlying mechanisms and the links between price increase policies, obesity 
and public health outcomes.
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objeCtives: To identify, describe and classify managed entry agreements (MEAs) 
applied to orphan drugs by national payers and to analyse their practice in 
Europe. Methods: To identify and describe MEAs, national HTA and reimburse-
ment decisions on orphan drugs across seven European countries were reviewed 
and their main characteristics extracted. To fill data gaps and validate the accuracy 
of the extraction, collaboration was sought from national payers. To classify MEAs, a 
bespoke taxonomy was implemented. Identified MEAs were analysed and compared 
by focusing on five key themes, namely by describing the MEAs in relation to: drug 
targets and therapeutic classes, geographical spread, type of MEA applied, declared 
rationale for setting-up of MEAs, and evolution over time. Results: Forty-two MEAs 
for 26 orphan drugs, implemented between 2006 and 2012 and representing a variety 
of MEA designs, were identified. Italy was the country with the highest number of 
schemes (n= 15), followed by The Netherlands (n= 10), England and Wales (n= 8), 
Sweden (n= 5) and Belgium (n= 4). No MEA was identified for France and Germany 
due to data unavailability. Antineoplastic agents were the primary targets of MEAs. 
55% of the identified MEAs were performance-based risk-sharing arrangements; 
the other 45% were financial-based. Nine of these 26 orphan drugs were subject 
to MEAs in two or three different countries, resulting in 24 MEAs. A total of 60% 
of identified MEAs focused on conditions whose prevalence is inferior to 1 per 
10,000. ConClusions: This study confirmed that a variety of MEAs were increas-
ingly used by European payers to manage aspects of uncertainty associated with 
the introduction of orphan drugs in the health care system, and which may be of a 
clinical, utilisation, or budgetary nature. It remains unclear whether differences in 
the use of MEAs reflect differences in how ‘uncertainty’ and ‘value’ are perceived 
across health care systems.
injections are lower compared to intravenous infusion due to potential lower time 
investments, shorter pharmacy preparation time, less patient chair time and less 
spillage. Methods: We use a prospective, observational, bottom up, micro-costing 
approach aiming at the inclusion of 50 patients with hematological disease. Primary 
cost outcomes comprise the labor costs for nurses and pharmacists/pharmacy 
technicians, materials, hourly daycare costs and drug spillage costs. Exact timings 
are measured using stopwatches, dosing and spillage is measured using registered 
MabThera volumes in the Hospital Pharmacies’ registrations and materials are exactly 
numbered and labeled. List prices are used for materials and MabThera costs, hourly 
nurse and pharmacy time is costed according to salaries, and day-care is costed 
using the Dutch guideline for costing research in health care. Anticipating positive 
outcomes of the currently ongoing non-inferiority study, efficacy of MabThera along 
both administration routes was implicitly assumed similar; additionally parity pricing 
is assumed. Results: Interim results based on 24 patients included so far indicate 
that extra costs of intravenous infusion over subcutaneous injections are on average 
€ 175 per administration. This difference is primarily constituted by € 100 lower daycare 
costs related to shorter chair time for subcutaneous as compared to intravenous 
administration. ConClusions: Our interim cost-minimization analysis suggests 
that subcutaneous injection of MabThera involves lower administration costs than 
intravenous infusion. With similar efficacy assumed, cost savings can be achieved at 
no expense of health, by including subcutaneous MabThera injections in the Dutch 
reimbursement system. Notably, over a full course of administrations (8 cycli) cost 
savings may easily surpass € 1000 per patient per year.
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objeCtives: To review the assessments of benefit for orphan drugs within 
the early benefit assessment process after implementation of AMNOG in 
Germany. Methods: Secondary research was used in this study. Results: In 
contrast to other pharmaceuticals, by law, the benefit of orphan drugs (ODs) is 
proven by market authorization. No assessment vs. an appropriate comparator as 
defined by G-BA will be conducted, provided the revenue is less than 50 mio. EUR 
based on pharmacy retail prices including VAT over the past twelve months. IQWiG 
only assesses the accuracy of the number of patients and the therapy costs stated in 
the value dossier, while GB-A defines the extent of the benefit based on the Phase 
III data submitted with the abbreviated dossier. Seven ODs have been assessed by 
G-BA since implementation of AMNOG in 2011. Only one OD has received consider-
able benefit status in one patient subgroup, whilst two ODs have been classified 
as not quantifiable, and the other ODs assessed so far have been granted only a 
minor benefit. Prices have been negotiated for only 2 ODs so far: For Pirfenidon, 
with an unquantifiable benefit, a rebate of 11% was applied, while Tafamidis, with 
a minor benefit, received a rebate of 24.5%. ConClusions: There is a clear benefit 
for ODs (with annual sales of less than 50 mio EUR) in terms of reduced administra-
tive burden and costs associated with the abbreviated value dossier submission. 
Furthermore, the OD status and the absence of a comparative added benefit assess-
ment warrant a benefit score, whereas 60% of the non-orphan pharmaceuticals 
failed to prove an additional benefit vs. the defined comparator. As only two orphan 
drugs have completed price negotiations, it is very difficult to estimate, whether 
OD status will have a positive impact on future pricing opportunities after AMNOG.
PSY78
coSt-effectiveneSS of School-bASed heAlth PRomotion in cAnAdA: A 
life-couRSe modeling APPRoAch
Tran B.1, Ohinmaa A.1, Kuhle S.2, Johnson J.A.1, Veugelers P.1
1University of Alberta, Edmonton, AB, Canada, 2Dalhousie University, Halifax, NS, Canada
objeCtives: The Alberta Project Promoting active Living and healthy Eating (APPLE) 
Schools has been recognized as a “best practice in preventing childhood obesity. To 
inform decision making on the expansion and resource allocation for such school-
based program like the APPLE Schools, we evaluated its cost-effectiveness and 
return-on-investment following a life-course approach. Methods: We developed 
a state transition model to represent the life-time progression of weight status of 
three groups of children who were obese, overweight or normal weight at 11 years. 
The model quantified impacts of the intervention in terms of prevented excess 
weight cases, improved quality-adjusted life years (QALY), and avoided health care 
costs. Both costs and QALYs were estimated to their present value using 3% dis-
count rate. Results: The incremental cost-effectiveness ratio (ICER) of the APPLE 
Schools program was CA$ 15,833 per 1 QALY gained, and CA$ 24,359 or 11,047 per 1 
obese or overweight case prevented in adult population. Every 1,000 children inter-
vened; the program costs CA$190,000, and the estimated saving in the health care 
costs is about CA$ 2.3 million, that is equivalent to a benefit-cost ratio of 13:1. The 
sensitivity analyses showed that the incremental cost-effectiveness of the APPLE 
Schools program was robust against variations of program costs and model param-
eters. ConClusions: The APPLE Schools program is a cost-effective intervention 
for obesity prevention, and promises substantial return on investment. Expanding 
the coverage and allocating resources towards school-based programs is central to 
the fight against obesity epidemic in Canada.
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objeCtives: To review the published literature to identify: a) the most frequently 
cited challenges relating to payer assessment and reimbursement of rare disease 
treatments (including orphan drugs), and b) to review author recommendations to 
improve the assessment of these treatments. Methods: A systematic literature 
